MÖLNDAL, SWEDEN
Cellectricon is pleased to announce a strategic collaboration with Biosector and Stefan Sandström, aimed at strengthening the company’s presence and long-term engagement in the Japanese life science market.
Stefan Sandström is now representing Cellectricon in Japan as Head of Japan Business Development, supporting the Japanese pharmaceutical and biotechnology ecosystem in accessing Cellectricon’s neuroscience-focused drug discovery services and platforms. The collaboration reflects Cellectricon’s commitment to building close, long-term relationships with partners in Japan, based on scientific depth, trust, and continuity.
With nearly two decades of experience working with Japanese pharmaceutical companies, Stefan brings deep insight into local decision-making processes, expectations, and collaboration culture. His background combines academic training in medicine and chemical engineering with extensive hands-on experience in business development, strategic partnerships, and commercialization within drug discovery.
“Japan is a highly sophisticated market where long-term commitment and scientific credibility are essential,” says Stefan Sandström. “Cellectricon’s focus on high-quality data, robust platforms, and collaborative project execution aligns very well with how successful partnerships are built in Japan.”
“We are thrilled to welcome Stefan to Cellectricon. Stefan’s appointment reflects our commitment to deepening our client relationships and advancing Cellectricon’s reputation in Japan as a trusted specialist CRO and leader in in-vitro neurobiology research.” says Mathias Karlsson, CEO of Cellectricon.
Through this collaboration, Cellectricon aims to further support Japanese partners in neurobiology drug discovery, providing local accessibility while maintaining the scientific excellence and operational standards that define Cellectricon globally.